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Abstract: Many enzymes make “mistakes”. Consequently, repair enzymes have evolved to
correct these mistakes. For example, lactate dehydrogenase (LDH) and mitochondrial malate
dehydrogenase (mMDH) slowly catalyze the reduction of 2-oxoglutarate (2-OG) to the oncometabolite
L-2-hydroxyglutarate (L-2-HG). L-2-HG dehydrogenase corrects this error by converting L-2-HG to
2-OG. LDH also catalyzes the reduction of the oxo group of 2-oxoglutaramate (2-OGM; transamination
product of L-glutamine). We show here that human glutamine synthetase (GS) catalyzes the
amidation of the terminal carboxyl of both the L- and D- isomers of 2-HG. The reaction of 2-OGM
with LDH and the reaction of L-2-HG with GS generate L-2-hydroxyglutaramate (L-2-HGM). We
also show that L-2-HGM is a substrate of human ω-amidase. The product (L-2-HG) can then be
converted to 2-OG by L-2-HG dehydrogenase. Previous work showed that 2-oxosuccinamate (2-OSM;
transamination product of L-asparagine) is an excellent substrate of LDH. Finally, we also show that
humanω-amidase converts the product of this reaction (i.e., L-2-hydroxysuccinamate; L-2-HSM) to
L-malate. Thus,ω-amidase may act together with hydroxyglutarate dehydrogenases to repair certain
“mistakes” of GS and LDH. The present findings suggest that non-productive pathways for nitrogen
metabolism occur in mammalian tissues in vivo. Perturbations of these pathways may contribute to
symptoms associated with hydroxyglutaric acidurias and to tumor progression. Finally, methods for
the synthesis of L-2-HGM and L-2-HSM are described that should be useful in determining the roles
ofω-amidase/4- and 5-C compounds in photorespiration in plants.
Keywords: ω-Amidase; asparagine transaminase; 2-hydroxyglutarate; 2-hydroxyglutaramate;
2-hydroxysuccinamate; glutamine synthetase; glutamine transaminases; 2-oxoglutaramate;
2-oxoglutarate
1. Introduction
More than 90 years ago, Otto Warburg noticed that many cancer cells copiously metabolize
glucose to lactate, even in the presence of adequate oxygen [1]. This process generates only two
ATP molecules per molecule of glucose converted to lactate. This apparently wasteful process is still,
however, adequate to meet most of the energy requirements of the cancer cells [2–6]. A major function
of the mitochondria in many cancer cells is, therefore, to provide metabolic building blocks for rapidly
dividing cells [6].
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The unusual metabolism of many tumor cells is further exemplified by the production of
oncometabolites (tumor transforming factors) such as L-2-hydoxyglutarate (L-2-HG; S-enantiomer),
succinate and fumarate [7,8]. 2-Oxoglutarate (2-OG; α-ketoglutarate) is a poor substrate of
mitochondrial malate dehydrogenase (mMDH) [9]. Nevertheless, mMDH is so abundant that this
side reaction (Equation (1)) is not inconsequential. If there were no way to remove the L-2-HG
produced, it would accumulate in tissues to potentially toxic levels. Thus, a repair enzyme (L-2-HG
dehydrogenase (Equation (2))) has evolved to convert L-2-HG back to 2-OG.
2-Oxoglutarate (2-OG) + NADH + H+  L-2-hydroxyglutarate (L-2-HG) + NAD+ (1)
L-2-HG + FAD→ 2-OG + FADH2 (2)
L-2-Hydroxyglutaric aciduria is a rare inborn error of metabolism in which L-2-HG dehydrogenase
is defective [9]. Children with L-2-hydroxyglutaric aciduria exhibit increased concentrations of L-2-HG
in body fluids that are associated with progressive deterioration of central nervous system function,
epilepsy, macrocephaly, leukoencephalopathy and a greatly increased risk of cerebral neoplasms [9–12].
L-2-HG inhibits 2-OG-utilizing enzymes, such as the Jumonji family of histone lysine demethylases [13].
Moreover, it has recently been shown that L-2-HG production is enhanced in hypoxic tissues [13],
presumably as a result of increased cytosolic NADH and the ability of lactate dehydrogenase (LDH)
to utilize 2-OG (albeit poorly) as a substrate [14]. Thus, L-2-HG may arise not only as a side reaction
catalyzed by mMDH, but also as a side reaction catalyzed by LDH. The increase in L-2-HG during
hypoxia appears to be sufficient to increase epigenetic methylation of histone repressive marks [13].
Moreover, the activity of mMDH and LDH toward 2-OG is stimulated several fold at acidic pH
(relative to physiological pH) [14]. Acidic pH is known to stabilize hypoxia-inducible factor (HIF) [15].
This may be of significance in the acidic milieu of tumors with implications for HIF signaling [14].
L-2-HG has been proposed to serve an important role in the regulation of cellular redox
homeostasis and cellular energy metabolism through its regulation of glycolysis and oxidative
phosphorylation [16]. The concentration of L-2-HG was shown to be sensitive to metabolic
perturbations in several mammalian cell lines in culture, and it was suggested that L-2-HG may
play a critical role in the adaptive response of mammalian cells to hypoxia [16]. This may be especially
relevant to tumor cells, which often grow in a hypoxic environment.
The D-enantiomer of 2-HG (D-2-HG; R-enantiomer) is normally produced in vivo by the action
of hydroxy acid:oxo acid transhydrogenase (Equation (3)) [17]. In the brain and other organs, the
succinic semialdehyde produced by this route is presumably converted to succinate which then enters
the tricarboxylic acid (TCA) cycle via the GABA shunt. It has also been suggested that D-2-HG is
generated in vivo as a metabolite of L-5-hydroxylysine (a component of collagen) [18] and possibly
of aminolevulinate [19,20]. However, there is no known biological role for D-2-HG in normal tissues.
Thus, this compound is salvaged by its conversion to 2-OG catalyzed by D-2-HG dehydrogenase
(Equation (4)).
4-Hydroxybutyrate + 2-OG  succinic semialdehyde + D-2-hydroxyglutarate (D-2-HG) (3)
D-2-HG + FAD→ 2-OG + FADH2 (4)
A rare inborn error of metabolism, in which D-2-HG dehydrogenase is defective, causes
D-2-hydroxyglutaric aciduria (type I). The disease phenotype ranges from asymptomatic to severe
neurological impairment, with symptoms ranging from early infantile-onset epileptic encephalopathy
to hypotonia [21]. In another rare inborn error of metabolism (D-2-hydroxyglutaric aciduria type II),
which is characterized by neurological problems, a mutation of isocitrate dehydrogenase 2 (IDH 2)
causes a greatly enhanced ability of the enzyme to generate D-2-HG [22]. Mutations in either IDH1
or IDH 2 (found in several types of cancers, including gliomas [23–26]) result in not only loss of
normal enzyme function (i.e., catalysis of the oxidative decarboxylation of isocitrate with concomitant
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production of NADH), but also to a pathological gain of a new enzyme function (i.e., reduction of 2-OG
to the oncometabolite D-2-HG, while consuming NADH). Apparently, in patients and cancer cells
harboring mutations in IDHs, the copious production of D-2-HG overwhelms the ability of D-2-HG
dehydrogenase to convert D-2-HG back to 2-OG and D-2-HG may reach mM concentrations within
tumors [25,26].
Despite the block in the TCA cycle, the mutations of IDH1/2 somehow convey a selective
advantage to the tumor cells, likely by altering cellular epigenetics and/or blocking normal
differentiation [23–26]. Many tumors make up for this loss of function by the up-regulation of key
mitochondrial enzymes (e.g., glutaminase, glutamate dehydrogenase 1 and 2) to convert L-glutamine
to 2-OG (“glutamine addiction”) [27,28]. Cancer cells harboring the IDH mutations, therefore, readily
supply 5-C units in the form of 2-OG that can bypass the IDH 1/2 perturbation in the TCA cycle, thereby
providing a means whereby D-2-HG can be produced without detriment to the cancer cells [23–26].
Recent work has suggested mechanisms whereby D-2-HG is oncogenic. For example, D-2-HG
was shown to strongly inhibit (IC50 25 µM) JMJD2A (a 2-OG-dependent enzyme of the Jumonji
family of histone Nε-lysine demethylases) and, to a lesser extent, HIF prolyl hydroxylase (IC50
5 mM) [29]. Decreased histone demethylation results in a block of cellular differentiation [30].
Koivunen et al. [31] showed that (R)-2-HG (i.e., D-2-HG), but not (S)-2-HG (i.e., L-2-HG), stimulates
HIF prolyl hydroxylase 2 activity, leading to diminished HIF levels, which, in turn, enhances the
proliferation and growth of human astrocytes in soft agar medium. Moreover, D-2-HG inhibits FTO
(Fat Mass and Obesity-associated protein), a 2-OG-dependent dioxygenase that is located in the nucleus
and is involved in the repair of single-stranded, alkylated RNA and DNA [32]. The main substrates
of FTO likely are the 6-methyladenosine moieties in RNA [33]. Finally, production of D-2-HG by
mutated IDH1/2 was shown to lead to the activation of mTOR by inhibiting KDM4A (lysine specific
demethylase 4A; another 2-OG-dependent enzyme of the Jumonji family of Nε-lysine demethylases),
an enzyme that specifically demethylates Lys 9 and 36 of histone H3 [34].
In yet another very rare inborn error of metabolism, D,L-2-hydroxyglutaric aciduria, both
L-2-HG and D-2-HG enantiomers accumulate. Patients with combined D,L-2-hydroxyglutaric aciduria
exhibit hypotonia, seizures and cerebral dysfunction [35,36]. The underlying molecular cause of this
devastating disease is attributed to a mutation in the gene SLC25A, which codes for the mitochondrial
citrate transport protein (mCTP) [35,36]. Recently, Jiang et al. [37] showed that mitochondrial
metabolism in mCTP-deficient cancer cells is markedly altered. Thus, lactate, 2-D-HG and 2-L-HG are
shown to accumulate, while as a consequence of inhibition of the pyruvate dehydrogenase complex,
TCA cycle intermediates are depleted. In these cells, anaplerosis is stimulated by the activation of
pyruvate carboxylase [37] and glucose is utilized to supply carbon for the mitochondrial production
of 2-OG which, on entry to the cytosol, is used to power reductive carboxylation of 2-OG, by IDH1
(the cytosolic form of IDH), to citrate [37]. As stated by the authors: “the resulting citrate is cleaved to
produce lipogenic acetyl-CoA, thereby completing a novel pathway of glucose-dependent reductive
carboxylation. In CTP-deficient cells, IDH1 inhibition suppresses lipogenesis from either glucose
or glutamine, implicating IDH1 as a required component of fatty acid synthesis in states of CTP
deficiency” [37].
It is now evident that many metabolically important enzymes (e.g., mMDH and LDH mentioned
above) are “promiscuous”. As a counter to this promiscuity, repair enzymes have evolved
to prevent accumulation of wasteful/toxic metabolites generated from the promiscuity of these
enzymes [38,39]. Here, we suggest additional possible cases of enzyme promiscuity and their possible
enzymatic corrections.
More than 65 years ago, Meister showed that LDH has remarkably broad substrate specificity.
For example, in addition to pyruvate, other 2-oxo acids such as glyoxylate, 3-hydroxypyruvate and
3-mercaptopyruvate were shown to be excellent substrates of crystalline beef heart LDH [40,41].
We have already alluded to the fact that LDH can catalyze the reduction of 2-OG to L-2-HG at a slow
rate [40]. Moreover, Meister showed that LDH can also catalyze the slow reduction of 2-oxoglutaramate
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(2-OGM;α-ketoglutaramate; the 2-oxo acid formed by transamination of L-glutamine) [42]. Meister also
showed that 2-oxosuccinamate (2-OSM; α-ketosuccinamate; the 2-oxo acid formed by transamination
of L-asparagine) is an excellent substrate of LDH [42]. The products of these two reactions are
presumably L-2-hydroxyglutaramate (L-2-HGM) and L-2-hydroxysuccinamate (L-2-HSM), respectively.
Glutamine synthetase (GS; glutamate-ammonia ligase) is also a promiscuous enzyme. For example,
in addition to utilizing L-glutamate as a substrate, the sheep brain enzyme also effectively utilizes
D-glutamate [43]. Moreover, chicken liver GS utilizes not only D-glutamate as a substrate but also
L-2-HG [44]. The product of the reaction with L-2-HG is presumably L-2-HGM. In the current work,
we present evidence that human GS also utilizes L-2-HG as a substrate, to a limited extent.
ω-Amidase (systematic name: ω-amidodicarboxylate amidohydrolase) (synonym: Nit2, nitrilase-like
protein 2) normally catalyzes the hydrolysis of 2-OGM to 2-OG (Equation (5)) and 2-OSM to oxaloacetate
(Equation (6)), respectively (see also the Discussion). 2-OG and oxaloacetate can then enter the TCA cycle
as an energy source.
2-Oxoglutaramate (2-OGM) + H2O→ 2-oxoglutarate (2-OG) + NH3 (5)
2-Oxosuccinamate (2-OSM) + H2O→ oxaloacetate + NH3 (6)
Here, we show that the corresponding L-2-hydroxy acid analogues of L-glutamine and
L-asparagine (i.e., L-2-HGM and L-2-HSM, respectively) are also substrates of human ω-amidase.
The corresponding reactions (water as attacking nucleophile) are shown in Equations (7)
and (8), respectively.
L-2-Hydroxyglutaramate (L-2-HGM) + H2O→ L-2-hydroxyglutarate + NH3 (7)
L-2-Hydroxysuccinamate (L-2-HSM) + H2O→ L-malate + NH3 (8)
In the case of L-2-HSM, the compound is converted byω-amidase to L-malate, which can then
enter the TCA cycle. In the case of L-2-HGM, the compound is converted to L-2-HG, which will
then be converted to 2-OG by L-2-HG dehydrogenase (Equation (2)), which can then enter the TCA
cycle. Thus, in addition to catalyzing metabolically important reactions (hydrolysis of 2-OGM and
2-OSM to 2-OG and oxaloacetate, respectively)ω-amidase may also be regarded as a repair enzyme
for salvaging L-2-HSM (as L-malate), and, working in conjunction with L-2-HG dehydrogenase, for
salvaging L-2-HGM (as 2-OG).
2. Materials and Methods
2.1. Reagents
All reagents were of the highest quality available. Bovine serum albumin (fraction V),
dithiothreitol (DTT), NAD+, L-glutamine, L-asparagine, L-malate, sodium 2-OG, potassium phosphate,
hydroxylamine hydrochloride (stock solutions neutralized with NaOH before use), tris hydrochloride,
glycine, sodium hydroxide, ferric chloride, lithium lactate, trichloroacetic acid, glycylglycine and
protease inhibitor cocktail were obtained from Sigma Aldrich Chemical Company (St. Louis, MO,
USA). Succinamic acid was obtained from Aldrich Chemical Company (Milwaukee, WI, USA).
2,4-Dinitrophenylhydrazine was obtained from Eastman Kodak (Rochester, NY, USA). Stock solutions
of 2-OGM, in which the pH was adjusted to around 6.0 with NaOH, were prepared by the method of
Krasnikov et al. [45].
2.2. Enzymes
Human ω-amidase/Nit2 (0.29 µg/µL) was purchased from Origene Technologies, Inc., Rockville,
MD. The preparation exhibits a single band on PAGE and is enzymatically active (data not shown).
Pig heart mMDH (3.2 mg protein/mL in 50% glycerol, 50 mM potassium phosphate, pH 7.5) was
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purchased from Sigma-Aldrich, St. Louis, Mo. Human GS was expressed and purified by the method
of Listrom et al. [46] except that during the purification procedure HA Ultrogel® (Pall Life Sciences;
Pall Biosepra, Saint Cristophe, France) was used in place of hydroxylapatite [47]. The specific activity
of purified recombinant human GS (ammonia and glutamate as substrates) was 17.9 U/mg [47,48].
2.3. Preparation of Rat Liver Cytosol
The procedure used for the isolation of cytosol from the liver of a single adult male rat was as
described by Krasnikov et al. [49].
2.4. Enzyme Assays
2.4.1. ω-Amidase
As noted above, ω-amidase catalyzes the hydrolysis of 2-OGM to 2-OG (Equation (5)) and the
hydrolysis of 2-OSM to oxaloacetate (Equation (6)). The hydrolysis of 2-OGM to 2-OG was measured
by the procedure of Krasnikov et al. [45] as follows: The reaction mixture contained 3 mM 2-OGM,
5 mM DTT, 100 mM tris-HCl buffer (pH 8.0) and enzyme in a final volume of 50 µL. After incubation
at 37 ◦C, the reaction was quenched by addition of 20 µL of 5 mM 2, 4-dinitrophenylhydrazine in 2 M
HCl. After a further incubation at 37 ◦C for 5 min, 130 µL of 1 M NaOH was added and the absorbance
was read at 430 nm after 5 min (ε 2-OG 2, 4-dintrophenylhydrazone ~16,000 M-1·cm-1). It should be
noted that although the open-chain form of 2-OGM contains a reactive carbonyl, at physiological pH
values and in the presence of the acidic reagent, most of the compound is cyclized to a lactam [45,50,51]
that does not react with 2, 4-dinitrophenylhydrazine.
In addition to catalyzing the hydrolysis of 2-OGM and 2-OSM, rat liver ω-amidase also catalyzes
the hydroxaminolysis of succinamate [42,45,50,51] (Equation (9)). The resulting hydroxamate is readily
quantitated as a brown complex in the presence of highly acidic ferric chloride [45]. In the present
work, this procedure was adapted to measure the hydroxaminolysis of L-2-HGM (Equation (10)).
Succinamate + NH2OH→ 3-succinylhydroxamate + NH3 (9)
L-2-Hydroxyglutaramate (L-2-HGM) + NH2OH→ 2-hydroxy-4-glutamylhydroxamate + NH3 (10)
The reaction mixture (50 µL) contained 50 mM L-2-HGM, 100 mM potassium phosphate buffer
(pH 7.4), 1 mM DTT, 100 mM hydroxylamine, enzyme and, where indicated, glycylglycine (an inhibitor
ofω-amidase; see below). After incubation at 37 ◦C for 1 hour, the reaction was terminated by addition
of 0.15 mL of FeCl3 reagent (0.37 M FeCl3, 0.67 M HCl, 0.2 M trichloroacetic acid [45]). Precipitated
protein (when present) was removed by centrifugation (10 min, 10,000 g) and the absorbance of the
0.18 mL of the supernatant was determined at 535 nm. The extinction coefficient at 535 nm of the ferric
complex of the succinylhydroxamate was previously calculated to be 920·M-1 cm-1 [45]. The blank
lacked either hydroxylamine or enzyme. In the present work, the extinction coefficient of the ferric
complex of L-2-HG hydroxamate at 535 nm is also assumed to be 920 M-1·cm-1.
The hydroxamate assay could not be used to determine whether L-2-HSM is a substrate of human
ω-amidase (see the results). Therefore, we used an alternative assay to determine whether L-2-HSM is
a substrate of humanω-amidase. The reaction mixture (50 µL) contained 50 mM L-2-HSM, 100 mM
potassium phosphate buffer, 1 mM DTT and 146 ng of enzyme. After incubation at 37 ◦C for 2 h, the
reaction was quenched by addition of 140 µL of glycine-NaOH buffer (pH 10.0) followed by 5 µL of
NAD+ and 5 µL of MDH solution. The increase in absorbance at 340 nm (due to formation of NADH;
ε 6.22 × 103 M-1·cm-1) was measured relative to that of a blank that lacked enzyme and compared to
values on a standard curve generated with various concentrations of L-malate in a reaction mixture
lackingω-amidase.
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2.4.2. Glutamine Synthetase (GS)
GS activity was determined by the end-point γ-glutamylhydroxamate assay [43] as modified
by Jeitner and Cooper [47] and Jeitner et al. [48] and is as follows: The reaction mixture (60 µL)
contained 100 mM tris-HCl, 10 mM MgCl2, 10 mM ATP, 100 mM hydroxylamine, 2 mM DTT, 5 µL
(9 µg) GS and varying amounts of L-glutamate. The reaction was initiated by the addition of enzyme
solution. After incubation at 37 ◦C for various time intervals, the reaction was quenched by the
addition of 180 µL of a solution containing 0.37 M ferric chloride, 0.67 M HCl and 0.2 M trichloroacetic
acid [43]. After centrifugation at 10,000 g for 5 min at 4 ◦C, to remove precipitated protein, the
absorbance of 200 µL of the supernatant fraction at 535 nm was recorded. The amount of γ-glutamyl
hydroxamate formed from L-glutamate under these conditions was calculated using 850 M-1·cm-1 as
the extinction coefficient [52]. In some experiments, L-glutamate was replaced by either L-2-HG or
D-2-HG. The extinction coefficient at 535 nm of the resulting ferric chloride hydroxamate complex is
assumed to be 850 M-1·cm-1.
2.5. Preparation of L-2-Hydroxyglutaramic Acid (L-2-HGM; S-5-Amino-2-Hydroxy-5-Oxopentanoic Acid)
The hydroxy acids used in this study are to be considered stereochemically pure, in accordance
with previously published, accepted considerations. The reaction mechanism for the preparation
of L-2-HGM from L-glutamine, as shown below in Scheme 1, is an example. After diazotization of
the amino nitrogen of L-glutamine, the carboxylic acid moiety of carbon-1 attacks, in an SN2 fashion,
to invert the stereochemistry at the 2-carbon, while creating the intermediate, protonated α-lactone
(Intermediate III), which subsequently reacts with a solvent molecule (water) in a second, SN2-mediated
substitution reaction to form L-2-HGM with overall retention of stereochemistry. Due to the reaction
conditions, and to the stability of the product formed, the L-2HGM undergoes an acid-catalyzed
cyclization to afford the γ-lactone VI, which is subsequently aminated with aqueous ammonia to
afford the salt VII, which is ultimately protonated with an ion exchange resin to afford L-2-HGM, after
removal of the solvent and trituration with ethanol. (The use of an ion exchange resin affords protons
to remove any excess ammonia and to neutralize the L-2-HGM salt, while not providing a large excess
of solubilized protons to catalyze the cyclization for a second time.)
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The experimental protocol for the synthesis of L-2-HGM is as follows: To a solution of L-glutamine
(4.10 g, 28.1 mmol) in a 100 mL solution of acetic acid in water (20:80/v:v) at 0 ◦C was added, dropwise,
a solution of sodium nitrite (1.94 g, 28.1 mmol) in water (25 mL) over a 1 h period. Once the addition
was complete, the solution was stirred at ambient temperature for 18 h. The volatiles were removed
by rotary evaporation (35 ◦C; water bath) and transferred, with the aid of ca. 5 mL of water, via a
glass ipette, t a stirring s lution of ammonia in water (am onium hydroxide, ca. 18 M, 36.5 mL,
ca. 657 mmol) and the resultant solution was stirred at ro m temperature for 24 h. The solvent and
excess ammonia were removed via rotary ev poration, the residue was dissolved in ca. 10 mL of
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water and applied to a column containing well washed Dowex 50W-X8 ion exchange resin (ca. 50 mL,
ca. 100 mmol H+) and eluted with water. The eluent with a pH below ca. 4 was collected and the
volatiles were removed via rotary evaporation to afford the crude material (3.77 g, 91.3% crude yield) as
a sticky white solid. The residue was triturated with 200 proof ethanol, the solid material was collected
by filtration and the residual solvent was removed in vacuo to afford L-2-HGM (2.34 g, 54.2% yield) as a
white solid: 1H NMR (500 MHz, D2O) δ = 4.14 (dd, J = 4.6, 7.7 Hz, 1 H), 2.31–2.18 (m, 2 H), 1.96 (dddd,
J = 4.6, 7.2, 8.7, 14.2 Hz, 1 H), 1.85–1.76 (m, 1 H); 13C NMR (100 MHz, D2O (0.5% t-BuOH)) δ = 179.6,
178.5, 70.45, 31.66, 30.39. HRMS (ESI) m/z calcd for C5H10NO4 [M + H]+ 148.0610, found 148.0609.
The 1H NMR and 13C NMR spectra are shown in supplemental Figures S1A and S1B, respectively.
2.6. Preparation of L-2-Hydroxysuccinamic Acid (L-2-HSM; S-4-Amino-2-Hydroxy-4-Oxobutanoic Acid)
In the case of the preparation of L-2-HSM, the second step of the procedure as described above for
the preparation of L-2-HGM is not necessary, as the product L-2-HSM does not cyclize to form any
detectable β-lactone. The experimental procedure is as follows: To a slurry of L-asparagine (7.80 g,
59.0 mmol) in a solution of acetic acid in water (20:80/v:v, 100 mL) at 0 ◦C was added a solution of
sodium nitrite (4.89 g, 70.8 mmol) in water (20 mL) in one portion. The resultant mixture was stirred for
18 h. The red mixture was applied to a column containing well washed Dowex 50W-X8 ion exchange
resin (200 mL, ca. 120 mmol H+) and eluted with water. The eluent was collected and the volatiles
were removed via rotary evaporation (50 ◦C; water bath) to afford the crude material as a red solid.
The residue was triturated with 200 proof ethanol, the solid material was collected by filtration and
the residual solvent was removed in vacuo to afford L-2-HSM (4.97 g, 63.3% yield) as an off white
solid: 1H NMR (500 MHz, D2O) δ = 4.41 (dd, J = 4.4, 7.9 Hz, 2 H), 2.63 (dd, J = 4.4, 15.4 Hz, 2 H),
2.52 (dd, J = 7.7, 15.3 Hz, 2 H); 13C NMR (100 MHz, D2O (0.5% t-BuOH)) δ = 177.7, 176.2, 68.2, 40.35.
HRMS (ESI) m/z calcd for C4H8NO4 [M + H]+ 134.0718, found 134.0795. The synthesis of L-2-HSM is
summarized in Scheme 2. The 1H NMR and 13C NMR spectra are shown in supplemental Figures S2A,
and S2B, respectively.
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Scheme 2. Protocol for the synthesis of L-2-hydroxysuccinamic acid (L-2-HSM).
2-HSM has been prepared previously by reduction of 2-OSM with 0.2 M sodium
borohydride [53,54]. Thus, the product was presumably a mixture of D- and L-enantiomers. Moreover,
2-OSM used in this procedure was generated enzymatically. The present procedure is an improvement
over the previous method because it does not involve an enzymatic step (and therefore can be used
in scaled up procedures that are not feasible by enzymatic procedures). Additionally, the product
generated by the present procedure is to be considered of the L-configuration.
2.7. Preparation of the L- and D-Enantiomers of 2-Hydroxyglutaric Acid
D- and L-2-hydroxyglutaric acids were prepared from (R)-(+)-5-oxo-tetrahydrofurancarboxylic
and (S)-(-)-5-oxo-tetrahydrofurancarboxylic acids (Sigma-Aldrich, St. Louis, MO, USA), respectively
(Supplementary Materials).
2.8. Spectrophotometry
All spectrophotometric measurements were carried out with a SpectraMax M5 96-well plate
spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Biology 2017, 6, 24 8 of 17
2.9. Statistics
Data are reported as the mean ± S.D. All enzyme assays were carried out in at least triplicate.
The unpaired t-test was used to determine significance values between means. A p value ≤ 0.05 is
considered significant.
3. Results
3.1. Human ω-Amidase Utilizes L-2-Hydroxyglutaramate (L-2-HGM) and L-2-Hydroxysuccinamate
(L-2-HSM) as Substrates
As noted above, rat liverω-amidase catalyzes the hydrolysis of 2-OGM and 2-OSM to 2-OG and
oxaloacetate, respectively [42,45,55–59] (Equations (5) and (6)). Moreover, rat liver ω-amidase also
catalyzes the hydroxaminolysis of succinamate and glutaramate [50,51]. Based on these findings, we
developed convenient assays to measure 2-OG formation from 2-OGM and the hydroxaminolysis of
succinamate [45]. These assays were employed in the present work to show that humanω-amidase,
similar to the rat liver enzyme, catalyzes the hydrolysis of 2-OGM and the hydroxaminolysis of
succinamate (Table 1). It was previously shown that neither L-glutamine nor L-asparagine is a
detectable substrate of semi-purified rat liverω-amidase [57]. Presumably, the charge on the α-amino
group of L-glutamine/L-asparagine prevents effective binding of this moiety to the region of the active
site that normally binds the oxygen of the of the 2-oxo group of the substrates 2-OGM/2-OSM. Thus,
it was of interest to determine whether L-2-HGM (in which the 2-oxo group of 2-OGM is replaced with
an uncharged 2-hydroxy group) is a substrate of human ω-amidase (hydroxaminolysis procedure).
Table 1 shows that L-2-HGM is indeed a substrate of humanω-amidase.
Table 1. Substrates of human Nit 2/ω-amidase.
Substrate Enzyme Added (ng) Specific Activity µmol/min/mg a
2-Oxoglutaramate (2-OGM) b 72.8 3.0 ± 0.9 (3)
Succinamate c 146 3.4 ± 0.3 (3)
L-2-Hydroxyglutaramate (L-2-HGM) c 291 1.4 ± 0.1 (7)
L-2-Hydroxysuccinamate (L-2-HSM) d 146 0.51 ± 0.18 (5)
a n, the number of replicates is shown in parenthesis. After incubation for 1 to 2 hours, product formation was
determined from which the specific activity was calculated. In a separate experiment, it was shown that the
reactions listed are linear over this time period. b The reaction mixture (50 µL) contained 100 mM tris buffer (pH 8.0),
12.6 mM 2-OGM, 1 mM DTT and enzyme (as indicated). After incubation at 37 ◦C, 2-OG formation was measured.
c The reaction mixture (50 µL) contained 100 mM potassium phosphate buffer (pH 7.4), 50 mM substrate, 100 mM
hydroxylamine, 1 mM DTT and enzyme (as indicated). After incubation at 37 ◦C hydroxamate formation was
measured with FeCl3 reagent. d The reaction mixture (50 µL) contained 100 mM potassium phosphate buffer
(pH 7.4), 50 mM substrate, 1 mM DTT and enzyme (as indicated). After incubation at 37 ◦C L-malate formation was
measured by an enzymatic procedure with mMDH.
Based on the findings shown in Table 1, that succinamate and L-2-HGM are substrates of
human ω-amidase (hydroxaminolysis reaction), we fully expected this enzyme to catalyze the
hydroxaminolysis of L-2-HSM. However, when the enzyme was incubated with L-2-HSM and
hydroxylamine in the presence of humanω-amidase, no product that absorbs at 535 nm upon addition
of acidic FeCl3 reagent could be detected (data not shown). As a consequence, we used another
procedure to determine whether L-2-HSM is a substrate of human ω-amidase. L-Malate was detected
as a product with mMDH (Table 1) confirming that L-2-HSM is a substrate of human ω-amidase
(Equation (8)).
We suspect that the hydroxamate formed with L-2-HSM cyclizes to a compound (5-hydroxy-1,2-
oxazinane-3,6-dione) that does not form a colored complex with the acidic FeCl3 reagent. It was
previously shown that L-γ-glutamyl hydroxamate is a substrate of L-amino acid oxidase [58].
The product was not characterized, but, as noted for 2-OGM [50,51], it is expected to cyclize to a
lactam (in this case 1,2-dihydroxy-5-oxoproline). This compound is also expected to arise from the
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hydroxaminolysis of 2-OGM. When we incubated 5 µL of rat liver cytosol with 3 mM 2-OGM in the
presence of 100 mM hydroxylamine and tris buffer (pH 8.0) for one h at 37 ◦C no product that absorbs
at 535 nm could be detected upon addition of the acidic FeCl3 reagent (data not shown). Under these
conditions, products absorbing at 535 nm were readily detected when 2-OGM was replaced by either
succinamate or L-2-HGM (Table 2). Thus, cyclized hydroxamates (5-hydroxy-1,2-oxazinane-3,6-dione
and 1,2-dihydroxy-5-oxoproline) do not form a complex with FeCl3 that absorbs at 535 nm.
Table 2. Hydroxaminolysis of succinamate and L-2-Hydroxyglutaramate (L-2-HGM) catalyzed by rat
liver cytosol in the absence or presence of an inhibitor a.
Addition Hydroxamate Formation nmol/min/mg
Succinamate (50 mM) 17 ± 2
Succinamate + glycylglycine (30 mM) 8.9 ± 0.8 b
Succinamate + L-2-HSM (50 mM) 12 ± 1 c
L-2-HGM 26 ± 1
L-2-HGM + glycylglycine (30 mM) 3.6 ± 0.2 d
L-2-HGM + L-2-HSM (25 mM) 18 ± 1 d
a The reaction mixture (50 µL) contained 25 mM L-2-HGM (or 50 mM succinamate), 100 mM potassium phosphate
(pH = 7.4), 1 mM DTT, 100 mM hydroxylamine, 5 µL of rat liver cytosol (39 mg protein/mL) and, where indicated,
glycylglycine or L-2-HSM. After incubation at 37 ◦C for 1 hour, hydroxamate formation was measured as described
in the text. n = 5; b Significantly different from the control (succinamate only) with p < 0.00001; c significantly
different from the control (succinamate only) with p < 0.0005; d significantly different from the control (L-2-HGM
only) with p < 0.00001.
3.2. Rat Liver Cytosol Catalyzes the Hydroxaminolysis of L-2-Hydroxyglutaramate (L-2-HGM)
The ability of a rat liver cytosolic preparation to catalyze the hydroxaminolysis of L-2-HGM was
tested. As a positive control, we first verified that this preparation catalyzes the hydroxaminolysis of
succinamate, an alternative ω-amidase substrate (Table 2). Glycylglycine is a competitive inhibitor
of rat liver ω-amidase with a Ki of around 3 mM [60]. This compound was shown to inhibit the
hydroxaminolysis of succinamate (Table 2), consistent with the presence of ω-amidase in the rat
liver cytosol. L-2-HSM was also found to inhibit the hydroxaminolysis of succinamate (Table 2).
This finding is consistent with the hypothesis that L-2-HSM acts as a competitive inhibitor of the
ω-amidase-catalyzed hydroxaminolysis of succinamate because it is an alternative substrate.
As expected, based on the present findings that highly purified human ω-amidase catalyzes a
hydroxaminolysis reaction with L-2-HGM (Table 1), the rat liver cytosol preparation was also shown to
catalyze a hydroxaminolysis reaction with L-2-HGM (Table 2). Evidence that this reaction is catalyzed
byω-amidase is the finding that, as with the hydroxaminolysis of succinamate, the hydroxaminolysis
reaction with L-2-HGM is inhibited by both glycylglycine and L-2-HSM (Table 2). Based on our
findings with the human enzyme, ω-amidase in the rat liver cytosol is expected to catalyze the
conversion of L-2-HSM to malate. However, we could not measure this reaction due to enzymes in
the cytosolic preparation that interfered with the mMDH used to quantitate the product (data not
shown). Nevertheless, the possibility that L-2-HSM binds at the active site ofω-amidase in the rat liver
homogenate is indicated by its inhibition of (1) the hydroxaminolysis reaction with both succinamate
and L-2-HGM (Table 2) and (2) the hydrolysis of 2-OGM (Table 3).
It is possible that glycylglycine, succinamate and/or L-2-HSM may interact with enzymes other
than ω-amidase in the rat liver homogenate to generate products that indirectly inhibit the ω-amidase
reaction. Although we cannot fully rule out this possibility, the data in Tables 2 and 3 are fully
consistent with patterns of inhibition noted with purifiedω-amidase preparations.
In summary, L-2-HGM was shown directly to be a substrate of human ω-amidase and of an
enzyme in rat liver cytosol (presumablyω-amidase). In addition, highly purified humanω-amidase
was shown to catalyze the hydrolysis of L-2-HSM to L-malate (Table 1). Moreover, L-2-HSM was shown
to inhibit the hydroxaminolysis of succinamate in rat liver cytosol (Table 2). Finally, strong but indirect
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evidence suggests that L-2-HSM binds to the rat liver enzyme in the liver homogenate most likely as
an alternative substrate to 2-OGM/succinamate (Table 3).
Table 3. Hydrolysis of 2-oxoglutaramate (2-OGM) to 2-oxoglutarate (2-OG) catalyzed by rat liver
cytosol in the absence or presence of an inhibitor a.
Addition 2-OG Formation nmol/min/mg
2-OGM (3 mM) 13 ± 1
2-OGM + glycylglycine (30 mM) 7.9 ± 0.7 b
2-OGM + L-2-HSM (25 mM) 4.5 ± 0.5 b
2-OGM + succinamate (50 mM) 2.9 ± 0.2 c
a The reaction mixture (50 µL) contained 3 mM 2-OGM, 1 mM DTT, 100 mM tris (pH = 8.0) and 5 µL rat liver cytosol.
After incubation at 37 ◦C for 15 minutes, 2-OG formation was measured as indicated in the text. In some cases,
L-2-HSM, glycylglycine or succinamate was included in the reaction mixture. N = 5 or 6. b Significantly different
from the control (2-OGM only) with p < 0.00001; c significantly different from the control (succinamate only) with
p < 0.00001.
3.3. L- and D-2-Hydroxyglutarate Are Weak Substrates of Human Glutamine Synthetase (GS)
As noted in the Introduction, unlike most enzymes that utilize amino acids as substrates, where
there is an absolute requirement for either the D- or L-enantiomer, sheep brain GS can effectively utilize
both the L- and D- enantiomers of glutamate as substrates [43]. As also mentioned, the chicken liver
enzyme has some activity with L-2-HG [44]. Thus, it was of considerable interest to determine whether
both the L- and D-2-HG enantiomers are substrates of human GS (Figure 1).
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The progress curves for L-glutamate as a substrate (Figure 1A) of human GS are similar to 
those we reported previously and are consistent with slowing of the reaction with time due to 
depletion of substrate [47]. Although no rigorous kinetic analyses are shown, the data clearly show 
that both enantiomers of 2-HG are substrates of human GS (Figure 1B). Under the conditions of the 
assay, the L-enantiomer is a better substrate than is the D-enantiomer. However, the rate of 
hydroxamate formation with the two 2-HG enantiomers (Figure 1B) is much slower than that 
observed with L-glutamate (Figure 1A). Interestingly, the rate of the reaction with D- and L-2-HG 
was found to slow considerably with time. This finding is reminiscent of our previous findings with 
the two diastereoisomers of L-4-fluoroglutamate (i.e., 2S, 4R-4-fluoroglutamate and 2S, 
4S-4-fluoroglutamate) which are detectable substrates of human GS, but share the distinguishing 
feature in which the rate of the enzyme-catalyzed reaction rapidly decreases with time [48]. The 
mechanism(s) resulting in the apparent inactivation of human GS by the two enantiomers of 2-HG 
and by the two diasteroisomers of L-4-fluoroglutamate require(s) further study. 
Figure 1. Substrate behavior of hu an gluta ine synthetase ( S) to ard 2-hydroxyglutarate (2- G)
enantiomers. Progress curves are shown for the formation of hydroxamate from either L-glutamate
(L-Glu) (Panel A) or from L-2-HG and D-2-HG (Panel B). The means and SE of thre independent
observations are shown. te t at t e scale t e axis in panel B is less than that of panel A to
accommodate the low rate of GS-catalyzed hydroxamate formation from the 2-HG enantiomers.
The progress curves for L-glutamate as a substrate (Figure 1A) of human GS are similar to those
we reported previously and are consistent with slo ing of the reaction with time due to depletion
of substrate [47]. Although no rigorous kinetic analyses are shown, the data clearly show that both
enantiomers of 2-HG are substrates of human GS (Figure 1B). Under the conditions of the assay,
the L-enantiomer is a better substrate than is the D-enantiomer. However, the rate of hydroxamate
formation with the two 2-HG enantiomers (Figure 1B) is much slower than that observed with
L-glutamate (Figure 1A). Interestingly, the rate of the reaction with D- and L-2-HG was found to
slow considerably with time. This finding is reminiscent of our previous findings with the two
diastereoisomers of L-4-fluoroglutamate (i.e., 2S, 4R-4-fluoroglutamate and 2S, 4S-4-fluoroglutamate)
which are detectable substrates of human GS, but share the distinguishing feature in which the rate of
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the enzyme-catalyzed reaction rapidly decreases with time [48]. The mechanism(s) resulting in the
apparent inactivation of human GS by the two enantiomers of 2-HG and by the two diasteroisomers of
L-4-fluoroglutamate require(s) further study.
4. Discussion
Mammalian tissues contain at least two glutamine transaminases that catalyze the transamination
of L-glutamine to 2-OGM (Equation (11)). When coupled with theω-amidase reaction (Equation (5))
the net reaction (Equation (12)) constitutes the glutaminase II pathway [55–59].
L-Glutamine + 2-oxo acid  2-oxoglutaramate (2-OGM) + L-amino acid (11)
2-OGM + H2O→ 2-OG + NH3
Net: L-Glutamine + 2-oxo acid + H2O→ 2-OG + L-amino acid + NH3 (12)
Mammalian tissues also catalyze the transamination of L-asparagine to 2-OSM (Equation (13)).
2-OSM is then hydrolyzed to oxaloacetate and ammonia byω-amidase (Equation (6)). The net reaction
(Equation (14)) is known as the asparaginase II pathway [56,60].
L-Asparagine + 2-oxo acid  2-oxosuccinamate (2-OSM) + L-amino acid (13)
2-OSM + H2O→ oxaloacetate + NH3
Net: L-Asparagine + 2-oxo acid + H2O→ oxaloacetate + L-amino acid + NH3 (14)
As a result of the cyclization of 2-OGM and the high activity of ω-amidase, the glutamine
transaminase reaction is largely irreversible in mammalian tissues. Moreover, the glutamine
transaminases have wide 2-oxo acid substrate specificity. Thus, one of the biological roles of the
mammalian glutamine transaminases may be to salvage 2-oxo acids produced through non-specific
transamination reactions (“mistakes”) catalyzed by other aminotransferases [61]. The glutaminase II
pathway (i.e., glutamine transaminases plusω-amidase) also closes the methionine salvage pathway
by transaminating 2-oxo-(4-methylthio)butanoate (α-keto-γ-methiolbutyrate) to L-methionine [61].
Additionally, the kidney type glutamine transaminase catalyzes transamination of a number of
sulfur-containing amino acids to compounds that cyclize to products, several of which may be
neuroactive [62].
The asparaginase II pathway is important in photorespiratory nitrogen metabolism in
plants [53,54,63]. However, little is known about the metabolic importance of the asparaginase II
pathway in mammals. One study suggests that the asparaginase reaction (Equation (15)) is the major
route for the metabolism of asparagine in rat liver cytosol, whereas the asparaginase II pathway
(Equation (13)) is the major route in rat liver mitochondria [64].
L-Asparagine + H2O→ L-aspartate + NH3 (15)
Transamination of asparagine to 2-OSM presents a potential problem. 2-OSM is highly reactive,
forming a dimer in vitro [65,66]. The dimer can undergo ring closures, dehydration, aromatization,
deamidation and decarboxylation to a plethora of heterocyclic compounds [65,66]. Even if the
concentration of 2-OSM in vivo is too dilute for an effective bimolecular reaction, it is possible that
the compound could react with other α-keto acids or other reactive biomolecules. One of the roles of
ω-amidase may, therefore, be to prevent the accumulation of 2-OSM and condensation of 2-OSM with
another molecule of 2-OSM (or other reactive compound). Indeed,ω-amidase has a noticeably low Km
toward 2-OSM (~3 µM for the mouse enzyme at pH 7.2) [59].
We suggest that another way to prevent the accumulation of 2-OSM is to reduce 2-OSM to
L-2-HSM. As noted above, 2-OSM is a good substrate of LDH [42]. In the present work, we show
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that L-2-HSM is a substrate of ω-amidase. Thus, 2-OSM may be converted to oxaloacetate via the
action ofω-amidase, or it may first be reduced to L-2-HSM by LDH, followed byω-amidase-catalyzed
hydrolysis of L-2-HSM to L-malate. Both products (i.e., oxaloacetate and malate) are useful TCA cycle
metabolites. In this regard, it is interesting to note that L-2-HSM has been shown to be a substrate
of plant ω-amidases [54,67]. Given that mammalian ω-amidases utilize both 4- and 5-C substrates,
it is highly likely that L-2-HGM will also be a substrate of these plantω-amidases. This hypothesis is
supported by the finding that humanω-amidase utilizes L-2-HGM as a substrate (Table 1).
It is of interest that, as noted above, an avian GS utilizes L-2-HG as a substrate [44]. In the
present work, we show that both the L- and D- enantiomers of 2-HG are also substrates of human GS
(hydroxamate assay), but the relative rate with the L- and D- enantiomers of 2-HG is relatively slow
(initial rates are a few percent relative to that exhibited with L-glutamate; Figure 1) compared with
that exhibited by the avian enzyme toward L-2-HG (~41% relative to that exhibited with L-glutamate
(44)). Hydroxylamine and ammonia are nearly kinetically indistinguishable as substrates of ovine
brain GS [43]. This is also very likely to be the case with the human enzyme. Thus, the present work
strongly suggests that human GS can catalyze the formation of D- and L-2-HGM from D- and L-2-HG,
respectively, albeit at a considerably slower rate than that observed with L-glutamate. The difference
in L-2-HG utilization by the human and avian glutamine synthetases may be due to a difference in the
active sites. Binding of L-glutamate to the human enzyme is mediated by Arg340, His253 and Arg299 [68].
Avian glutamine synthetase, however, has a glycine substitution at position 340. In human glutamine
synthetase, the guanidino group of Arg340 interacts with the γ-carboxyl group of L-glutamate thereby
stabilizing this amino acid within the substrate binding site. The substitution of Gly for Arg at this
position removes a crucial contact site for L-glutamate and, likely, for L-2-HG, in the avian enzyme.
In support of this conclusion, the Km values for L-glutamate are 1.67 mM and 6.20 mM for human and
avian glutamine synthetase, respectively [44,47]. The Arg340 to Gly340 substitution may also facilitate
the catalysis of L-2-HG to L-2-HGM by avian glutamine synthetase. This substitution removes a bulky,
charged side chain that may facilitate either access of ammonia to the phosphorylated intermediate of
glutamate or the egress of L-2-HGM from the active site. However, a detailed comparative analysis of
the topology of the active sites of the human and avian enzymes must await further study.
We also noted above that 2-OGM is a weak substrate of LDH [42]. Thus, L-2-HGM may arise from
side reactions in mammalian tissues through at least two enzymatic reactions (i.e., via a side reaction
of GS with L-2-HG or by reduction of 2-OGM by LDH). In the current work, we show that L-2-HGM is
a substrate of humanω-amidase. Strong enzymatic activity toward L-2-HGM was also noted in rat
liver homogenates, most likely due, in large part, to endogenousω-amidase. Thus, we propose that
mammalian ω-amidase not only converts 2-OGM directly to metabolically useful 2-OG, but also acts
in conjunction with L-2-HG dehydrogenase to metabolize L-2-HGM to 2-OG.
Interestingly, it has recently been found that enzymes in the serine biosynthetic pathway in
Saccharomyces cerevisiae can generate D-2-HG [69]. This D-2-HG can then be converted to 2-OG
by an FAD-dependent transhydrogenase that uses pyruvate as a hydrogen acceptor. The D-2-HG
in the cytosol is coupled to the shuttling of reducing equivalents from cytosolic NADH to the
mitochondrion via D-lactate dehydrogenase. Thus, in this case, production of D-2-HG is part of
a useful biochemical mechanism.
5. Conclusions
The present work has uncovered some interesting enzyme-catalyzed side reactions (and also
describes some additional side reactions “buried” in the literature). However, no detailed kinetic
analyses were performed in the present work. Nevertheless, because the enzyme side reactions
investigated here/described in the literature are catalyzed by enzymes of inherently very high activity
(e.g., LDH, GS and ω-amidase), we believe that the side reactions may indeed occur in vivo, albeit at a
low rate. We suggest that the side reactions uncovered in the present work (summarized in Figure 2)
should act as a framework for future studies and be taken into account when studying the metabolic
Biology 2017, 6, 24 13 of 17
profiles of tumor cells. Although we have assumed that formation of L-2-HSM and L-2-HGM are
metabolic mistakes (Figure 2, legend), and that repair enzymes are necessary to correct these mistakes,
we cannot rule out the possibility that these compounds may have some unknown, but useful, function.
We also cannot rule out the possibility that they may contribute to the oncogenic properties of small
4-C and 5-C metabolites. Thus, in summary, the present work may serve as a basis for the discovery of
biologically important processes that hitherto were assumed to have no biological relevance. Finally,
we provide organic synthesis procedures for the preparation of L-2-HGM and L-2-HSM, which should
be useful for further metabolic studies of these compounds in plants, mammals and other organisms.
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Figure 2. Metabolically important reactions and side reactions involved in the metabolism of 
2-oxosuccinamate (2-OSM) (A) and 2-oxoglutaramate (2-OGM) (B). The asparaginase II pathway 
(bottom of panel A) and the glutaminase II pathway (bottom of panel B) may be regarded as major 
metabolic pathways for L-asparagine and L-glutamine, respectively. On the other hand, excessive 
formation of L-2-HSM and L-2-HGM as side reactions may be regarded as metabolic mistakes, so that 
repair pathways for their conversion to metabolically useful L-malate/oxaloacetate (Panel A) and 
2-OG (Panel B) are required. Not shown is the formation of D-2-HG by mutant IDHs and the possible 
utilization of this compound as a substrate of GS (Gln Synthetase). For clarity, some cofactors and 
co-substrates have been omitted from the diagram. 
Supplementary Materials: The following are available online at www.mdpi.com/2079-7737/6/2/24/s1, Figure S1A: 
1H NMR spectrum of L-2-hydroxyglutaramic acid (L-2-HGM) produced from L-glutamine. The stereochemistry is 
assumed to be in accordance with the literature; Figure S1B: 13C-NMR spectrum of L-2-hydroxyglutaramic acid 
(L-2-HGM) produced from L-glutamine. The stereochemistry is assumed to be in accordance with the literature; 
Figure S2A: 1H NMR spectrum of L-2-hydroxysuccinamic acid (L-2-HSM) produced from L-asparagine. The 
stereochemistry is assumed to be in accordance with the literature; Figure S2B: 3C-NMR spectrum of 
L-2-hydroxysuccinamic acid (L-2-HSM) produced from L-asparagine. The stereochemistry is assumed to be in 
accordance with the literature; Figure S3: Time course for ring openings of (S)-(+)-5-oxo-tetrahydrofurancarboxylic 
and (R)-(-)-5-oxo-tetrahydrofurancarboxylic acids. Stock solutions of approximately 100 mM 
(S)-(+)-5-oxo-tetrahydrofurancarboxylic acid and (R)-(-)-5-oxo-tetrahydrofurancarboxylic acid were prepared in 
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2-oxosuccinamate (2-OSM) (A) and 2-oxoglutaramate (2-OGM) (B). The asparaginase II pathway
(bottom of panel A) and the glutaminase II pathway (bottom of panel B) may be regarded as major
metabolic pathways for L-asparagine and L-glutamine, respectively. On the other hand, excessive
formation of L-2-HSM and L-2-HGM as side reactions may be regarded as metabolic mistakes, so that
repair pathways for their conversion to metabolically useful L-malate/oxaloacetate (Panel A) and
2-OG (Panel B) are required. Not shown is the formation of D-2-HG by mutant IDHs and the possible
utilizatio of this compound as a substrate of GS (Gln Synthetase). For clarity, some cofactors and
co-substrates have been mitted from the diagram.
Supple entary aterials: The following are available online at www. dpi.com/2079-7737/6/2/24/s1,
Figure S1A: 1H NMR spectrum of L-2-hydroxyglutaramic acid (L-2-HGM) produced from L-glutamine.
Biology 2017, 6, 24 14 of 17
The stereochemistry is assumed to be in accordance with the literature; Figure S1B: 13C-NMR spectrum
of L-2-hydroxyglutaramic acid (L-2-HGM) produced from L-glutamine. The stereochemistry is assumed
to be in accordance with the literature; Figure S2A: 1H NMR spectrum of L-2-hydroxysuccinamic acid
(L-2-HSM) produced from L-asparagine. The stereochemistry is assumed to be in accordance with the
literature; Figure S2B: 3C-NMR spectrum of L-2-hydroxysuccinamic acid (L-2-HSM) produced from L-asparagine.
The stereochemistry is assumed to be in accordance with the literature; Figure S3: Time course for ring openings
of (S)-(+)-5-oxo-tetrahydrofurancarboxylic and (R)-(-)-5-oxo-tetrahydrofurancarboxylic acids. Stock solutions of
approximately 100 mM (S)-(+)-5-oxo-tetrahydrofurancarboxylic acid and (R)-(-)-5-oxo-tetrahydrofurancarboxylic
acid were prepared in water (pH 1.9). The solutions were portioned into 0.2 mL samples and incubated at 80 ◦C
for varying times. At the indicated times the sample were removed and placed on ice. Fifteen µL aliquots of the
samples were then combined with 235 µL water and 750 µL 5 mM FeCl3. The resulting change in absorbance was
measured at 428 nm, from which the concentration of ring-opened products L-2-HG (panel A) and D-2-HG (panel B)
was calculated. Shown are the mean and standard deviation of between 4 and 8 measurements for each time point,
Figure S4: Spectra for ferric ion complexed with L-lactate and L-2-hydroxyglutarate (L-2-HG). The spectra are of
either 2.5 µmol L-lactate (lithium salt) or 2.5 µmol L-2-HG combined with 3.5 µmol FeCl3 in 1 mL water. The blank
is 3.5 µmol of FeCl3 in water. L-2-HG was prepared by heating 100 mM (S)-(+)-5-oxo-tetrahydrofurancarboxylic
acid for 24 hours at 80 ◦C; Figure S5: Standard curve for lactate-ferric ion complex. Dilutions of lithium lactate
were prepared in water and then combined in 250 µL lots with 750 µL FeCl3. Shown are the mean and standard
deviation of between 6 and 11 measurements.
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